Lei Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lei Yu has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Yun-Feng Zhang
Department of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
10 shared publicationsJi Ke
Beijing Tongren Hospital
7 shared publicationsYun Jing
Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
7 shared publicationsJian-Ye Li
Department of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China
6 shared publicationsShan Ma
Department of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, People’s Republic of China
6 shared publications- Xin Du
Department of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China
6 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Stage-dependent prognostic value of clinical and pathological T staging in resected lung adenocarcinoma: a multicenter cohort study
Preoperative CT-based clinical T staging guides surgical planning in lung adenocarcinoma, whereas pathological T staging remains the postoperative referenc
- 14 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessStage-dependent prognostic value of clinical and pathological T staging in resected lung adenocarcinoma: a multicenter cohort study
Preoperative CT-based clinical T staging guides surgical planning in lung adenocarcinoma, whereas pathological T staging remains the postoperative referenc
- 30 April 2026
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 284, 109039
Current drug treatment methods and potential significance of glucocorticoid for inoperable advanced thymoma
- 30 April 2026
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 284, 109039
Current drug treatment methods and potential significance of glucocorticoid for inoperable advanced thymoma
- Open Access
- 3 October 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-11
Expression and prognostic value of MCM2 in type B thymomas
Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs. mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2’s association with prognosis and clinicopathological features. Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05–0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08–0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas. MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.
- 3 October 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-11
Open AccessExpression and prognostic value of MCM2 in type B thymomas
Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs. mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2’s association with prognosis and clinicopathological features. Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05–0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08–0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas. MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.
- Open Access
Clinicopathological Features and Pathogenesis of Thymoma Complicated with Alopecia Areata: A Multicenter, Matched Case Analysis
Background: Thymoma is a malignant tumor originating from the thymic epithelium and can be associated with over 100 paraneoplastic syndromes (PNSs). Due to the low incidence of thymoma and the relative rarity of alopecia areata (AA) as an associated autoimmune disease, patients with thymoma combined with AA are relatively uncommon in clinical practice. As a result, the clinicopathological features and pathogenesis of such patients have been rarely investigated. Methods: This study retrospectively analyzed the clinical records of thymoma patients who underwent surgical treatment at Peking Union Medical College Hospital and Beijing Tongren Hospital from August 2014 to July 2019, with a focus on the clinicopathological features of thymoma patients with AA. Propensity score matching (PSM) was employed to create a 1:5 matched comparison group with thymoma patients without AA. Results: A total of 428 thymoma patients were included, among which 9 had AA. Using PSM, we matched 45 control patients without AA based on age and gender. The analysis revealed that thymoma patients with AA had a significantly higher proportion of myasthenia gravis (MG) [100.00% (9/9) vs. 66.67% (30/45), p = 0.049], although there were no significant differences between the AChR antibodies, Titin antibodies, MG severity, and the incidence of postoperative myasthenic crisis. However, the proportion of thymoma patients with AA who also had other PNSs besides MG was significantly higher [88.89% (8/9) vs. 6.67% (3/45), p < 0.001]. Additionally, CD4+/CD8+ T-cell inversion in the serum was observed at a much higher rate in thymoma patients with AA [100.00% (9/9) vs. 24.44% (11/45), p < 0.001]. Conclusions: We hypothesize that the pathogenesis of thymoma with AA differs from that of thymoma with MG, though there may be a correlation. The etiology of thymoma with AA may be attributed to abnormal autoimmune CD8+ T lymphocytes produced by the thymoma, which can also lead to other cytotoxic T-cell-mediated autoimmune diseases.
Open AccessClinicopathological Features and Pathogenesis of Thymoma Complicated with Alopecia Areata: A Multicenter, Matched Case Analysis
Background: Thymoma is a malignant tumor originating from the thymic epithelium and can be associated with over 100 paraneoplastic syndromes (PNSs). Due to the low incidence of thymoma and the relative rarity of alopecia areata (AA) as an associated autoimmune disease, patients with thymoma combined with AA are relatively uncommon in clinical practice. As a result, the clinicopathological features and pathogenesis of such patients have been rarely investigated. Methods: This study retrospectively analyzed the clinical records of thymoma patients who underwent surgical treatment at Peking Union Medical College Hospital and Beijing Tongren Hospital from August 2014 to July 2019, with a focus on the clinicopathological features of thymoma patients with AA. Propensity score matching (PSM) was employed to create a 1:5 matched comparison group with thymoma patients without AA. Results: A total of 428 thymoma patients were included, among which 9 had AA. Using PSM, we matched 45 control patients without AA based on age and gender. The analysis revealed that thymoma patients with AA had a significantly higher proportion of myasthenia gravis (MG) [100.00% (9/9) vs. 66.67% (30/45), p = 0.049], although there were no significant differences between the AChR antibodies, Titin antibodies, MG severity, and the incidence of postoperative myasthenic crisis. However, the proportion of thymoma patients with AA who also had other PNSs besides MG was significantly higher [88.89% (8/9) vs. 6.67% (3/45), p < 0.001]. Additionally, CD4+/CD8+ T-cell inversion in the serum was observed at a much higher rate in thymoma patients with AA [100.00% (9/9) vs. 24.44% (11/45), p < 0.001]. Conclusions: We hypothesize that the pathogenesis of thymoma with AA differs from that of thymoma with MG, though there may be a correlation. The etiology of thymoma with AA may be attributed to abnormal autoimmune CD8+ T lymphocytes produced by the thymoma, which can also lead to other cytotoxic T-cell-mediated autoimmune diseases.
- Open Access
- 6 May 2025
- Published by Springer Nature in Genes & Immunity
- Vol. 26 (3) , 222-228
Novel modulation of T effector memory cells-expressing CD45RA by prednisone in inoperable advanced type B thymoma patients
Due to the covert onset of thymoma, nearly 30% of patients are diagnosed at stage III or IV, losing the opportunity for surgical treatment. We have initiated the application of prednisone in treating refractory thymoma and explored biomarkers to identify potential cases that might benefit from prednisone treatment. In a study involving 96 patients with thymoma, we confirmed a significant tumor shrinkage with prednisone acetate treatment. A reduced diameter ratio indicated that type B1 and B2 thymomas exhibited the most obvious response to prednisone acetate, especially type B2 thymoma. However, the reduced diameter ratio was < 30% in type A, AB, and B3 thymomas. Immunofluorescence and flow cytometry of tumor tissues indicated that TEMRA (T Effector Memory-Expressing CD45RA) cells primarily exist in type B thymoma. However, the percentage of interleukin-8 + TEMRA cells decreased only in B1 and B2 thymoma tissues after prednisone acetate treatment. These findings are particularly significant for patients with type B thymoma with stage III or IV.
- 6 May 2025
- Published by Springer Nature in Genes & Immunity
- Vol. 26 (3) , 222-228
Open AccessNovel modulation of T effector memory cells-expressing CD45RA by prednisone in inoperable advanced type B thymoma patients
Due to the covert onset of thymoma, nearly 30% of patients are diagnosed at stage III or IV, losing the opportunity for surgical treatment. We have initiated the application of prednisone in treating refractory thymoma and explored biomarkers to identify potential cases that might benefit from prednisone treatment. In a study involving 96 patients with thymoma, we confirmed a significant tumor shrinkage with prednisone acetate treatment. A reduced diameter ratio indicated that type B1 and B2 thymomas exhibited the most obvious response to prednisone acetate, especially type B2 thymoma. However, the reduced diameter ratio was < 30% in type A, AB, and B3 thymomas. Immunofluorescence and flow cytometry of tumor tissues indicated that TEMRA (T Effector Memory-Expressing CD45RA) cells primarily exist in type B thymoma. However, the percentage of interleukin-8 + TEMRA cells decreased only in B1 and B2 thymoma tissues after prednisone acetate treatment. These findings are particularly significant for patients with type B thymoma with stage III or IV.
- Open Access
- 15 September 2023
- Published by Springer Nature in Research Square
The level of IL-8 in TMERA cells as a biomarker for hormonotherapy in thymoma
Thymoma is the most common type of neoplasm in the anterior mediastinum. However, it can be challenging to differentiate thymoma from other anterior mediastinum tumors in this region through imaging examinations. Therefore, the identification of a reliable, unique characteristic for the further study of thymoma is crucial. Our study confirms an increase in TEMRA cells in type B thymoma and suggests that the level of IL-8 in TEMRA cells may be a biomarker indicating hormonotherapy can be an effective treatment for patients with type B1 and B2 thymoma patients.
- 15 September 2023
- Published by Springer Nature in Research Square
Open AccessThe level of IL-8 in TMERA cells as a biomarker for hormonotherapy in thymoma
Thymoma is the most common type of neoplasm in the anterior mediastinum. However, it can be challenging to differentiate thymoma from other anterior mediastinum tumors in this region through imaging examinations. Therefore, the identification of a reliable, unique characteristic for the further study of thymoma is crucial. Our study confirms an increase in TEMRA cells in type B thymoma and suggests that the level of IL-8 in TEMRA cells may be a biomarker indicating hormonotherapy can be an effective treatment for patients with type B1 and B2 thymoma patients.
- Open Access
- 8 May 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (12) , 13408-13414
Risk factor analysis of thymoma resection and its value in guiding clinical treatment
Background: In this study, relationships between clinicopathologic characteristics and progression‐free survival (PFS) of patients after thymomectomy were analyzed to provide valuable suggestions regarding the treatment of thymoma.Methods: Data from 187 thymoma patients undergoing surgery at Beijing Tongren Hospital between January 1, 2006, and December 31, 2015, were retrospectively reviewed. We explored the risk factors for PFS among sex, age, thymoma‐associated MG, completeness of resection, histologic type and TNM stage, and investigated their interrelationship.Results: Among the 187 patients, 18 patients (9.63%) had tumor recurrence/metastasis, and all of whom had in situ recurrence or pleural metastasis, and most of them (10 of 18 patients) had MG symptoms that reappeared or were aggravated. Fifteen patients (8.02%) died, and myasthenic crisis was a leading cause. Based on Cox regression analysis, only age (HR = 3.16; 95% CI: 1.44–6.91;p = 0.004) and the completeness of resection (HR = 9.03; 95% CI: 2.58–31.55;p = 0.001) were independent risk factors for PFS. Furthermore, we found that the completeness of resection was related to the histologic type (p = 0.009) and TNM stage (p < 0.001) by Fisher's exact test.Conclusions: The results of this cohort study remind us that we should pay attention to the reappearance or aggravation of MG after thymoma resection, because it is the leading cause of death and may indicate tumor progression. Furthermore, completeness of resection was related to the histologic type and TNM stage, but it was the independent risk factors of thymoma. Therefore, R0 resection is critical to the prognosis of thymoma.
- 8 May 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (12) , 13408-13414
Open AccessRisk factor analysis of thymoma resection and its value in guiding clinical treatment
Background: In this study, relationships between clinicopathologic characteristics and progression‐free survival (PFS) of patients after thymomectomy were analyzed to provide valuable suggestions regarding the treatment of thymoma.Methods: Data from 187 thymoma patients undergoing surgery at Beijing Tongren Hospital between January 1, 2006, and December 31, 2015, were retrospectively reviewed. We explored the risk factors for PFS among sex, age, thymoma‐associated MG, completeness of resection, histologic type and TNM stage, and investigated their interrelationship.Results: Among the 187 patients, 18 patients (9.63%) had tumor recurrence/metastasis, and all of whom had in situ recurrence or pleural metastasis, and most of them (10 of 18 patients) had MG symptoms that reappeared or were aggravated. Fifteen patients (8.02%) died, and myasthenic crisis was a leading cause. Based on Cox regression analysis, only age (HR = 3.16; 95% CI: 1.44–6.91;p = 0.004) and the completeness of resection (HR = 9.03; 95% CI: 2.58–31.55;p = 0.001) were independent risk factors for PFS. Furthermore, we found that the completeness of resection was related to the histologic type (p = 0.009) and TNM stage (p < 0.001) by Fisher's exact test.Conclusions: The results of this cohort study remind us that we should pay attention to the reappearance or aggravation of MG after thymoma resection, because it is the leading cause of death and may indicate tumor progression. Furthermore, completeness of resection was related to the histologic type and TNM stage, but it was the independent risk factors of thymoma. Therefore, R0 resection is critical to the prognosis of thymoma.
- Open Access
- 1 December 2022
- Published by Springer Nature in Cell & Bioscience
- Vol. 12 (1) , 1-21
In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer
Systemic identification of tumor suppressor genes (TSGs) and elucidation of their signaling provide a new angle for understanding of tumorigenesis, which is important for developing successful treatment for lung cancer patients. In our current work, we conducted an in vivo screen for lung cancer TSGs through CRISPR/Cas9 mediated knockout of genes at genome-wide scale. We found that ZNF24 was a potent and clinically relevant TSG of lung cancer. Ectopic expression of ZNF24 arrested lung cancer cells in S phase. Mechanistically, ZNF24 bound to promoter region of P65 to negatively regulate its transcription and thereby the signaling activity of NF-κB pathway. This signaling cascade is clinically relevant. Importantly, we found that combinational inhibition of KRAS, NF-κB, and PD-1 effectively shrank autochthonous KrasG12D/ZNF24−/− lung cancers in transgenic mouse model. Our current work thus revealed an important role played by loss of function of ZNF24 in lung tumorigenesis and shed new light in precision medicine for a portion of lung cancer patients.
- 1 December 2022
- Published by Springer Nature in Cell & Bioscience
- Vol. 12 (1) , 1-21
Open AccessIn vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer
Systemic identification of tumor suppressor genes (TSGs) and elucidation of their signaling provide a new angle for understanding of tumorigenesis, which is important for developing successful treatment for lung cancer patients. In our current work, we conducted an in vivo screen for lung cancer TSGs through CRISPR/Cas9 mediated knockout of genes at genome-wide scale. We found that ZNF24 was a potent and clinically relevant TSG of lung cancer. Ectopic expression of ZNF24 arrested lung cancer cells in S phase. Mechanistically, ZNF24 bound to promoter region of P65 to negatively regulate its transcription and thereby the signaling activity of NF-κB pathway. This signaling cascade is clinically relevant. Importantly, we found that combinational inhibition of KRAS, NF-κB, and PD-1 effectively shrank autochthonous KrasG12D/ZNF24−/− lung cancers in transgenic mouse model. Our current work thus revealed an important role played by loss of function of ZNF24 in lung tumorigenesis and shed new light in precision medicine for a portion of lung cancer patients.
- Open Access
- 22 November 2022
- Published by Springer Nature in Research Square
Investigation of the prognostic biomarkers for thymoma
Background Thymoma represents the most common anterior mediastinal malignancy and has a close association with autoimmune disease. However, the potential molecular oncogenesis of thymoma has not been fully clarified yet. This study aims to identify hub genes and signaling pathways associated with thymoma to explore the possible pathogenesis of thymoma and analyze their prognostic significance. Results A total of 738 DEGs were screened for subsequent analysis. Functional enrichment analysis emphasizes the important roles of the cell cycle signaling pathway, p53 signaling pathway, and TGF-β signaling pathway in the development of thymoma. Six hub genes had a close connection with prognosis. The relative higher expression of JUN(HR:4.95[1-24.47], p = 0.031) and the lower expression of CDK1(HR:0.17[0.03–0.83], p = 0.015), E2F2(HR:0.16[0.03–0.83], p = 0.015), MCM2(HR:0.16[0.03–0.82], p = 0.014), MKI67(HR:0.18[0.04–0.89], p = 0.02) and TOP2A(HR:0.12[0.02–0.58], p = 0.0018) was associated with a worse OS in thymoma patients. Besides, E2F2 was particularly overexpressed in type B2 thymoma compared with the other subtypes and normal thymus tissue. Immune infiltration analysis indicated that only E2F2 (r=-0.198, p = 3.35E-02) was negatively correlated with tumor purity. Moreover, the expression of CDK1, E2F2, JUN, and MCM2 was significantly correlated with the infiltration of B cells, CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and DCs. Conclusion Among the top 10 hub genes confirmed in thymoma, CDK1, E2F2, MCM2, MKI67, JUN, and TOP2A show prognostic significance and might also play vital roles in immune surveillance and tumor progression. E2F2 might be the potential biomarker for type B2 thymoma.
- 22 November 2022
- Published by Springer Nature in Research Square
Open AccessInvestigation of the prognostic biomarkers for thymoma
Background Thymoma represents the most common anterior mediastinal malignancy and has a close association with autoimmune disease. However, the potential molecular oncogenesis of thymoma has not been fully clarified yet. This study aims to identify hub genes and signaling pathways associated with thymoma to explore the possible pathogenesis of thymoma and analyze their prognostic significance. Results A total of 738 DEGs were screened for subsequent analysis. Functional enrichment analysis emphasizes the important roles of the cell cycle signaling pathway, p53 signaling pathway, and TGF-β signaling pathway in the development of thymoma. Six hub genes had a close connection with prognosis. The relative higher expression of JUN(HR:4.95[1-24.47], p = 0.031) and the lower expression of CDK1(HR:0.17[0.03–0.83], p = 0.015), E2F2(HR:0.16[0.03–0.83], p = 0.015), MCM2(HR:0.16[0.03–0.82], p = 0.014), MKI67(HR:0.18[0.04–0.89], p = 0.02) and TOP2A(HR:0.12[0.02–0.58], p = 0.0018) was associated with a worse OS in thymoma patients. Besides, E2F2 was particularly overexpressed in type B2 thymoma compared with the other subtypes and normal thymus tissue. Immune infiltration analysis indicated that only E2F2 (r=-0.198, p = 3.35E-02) was negatively correlated with tumor purity. Moreover, the expression of CDK1, E2F2, JUN, and MCM2 was significantly correlated with the infiltration of B cells, CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and DCs. Conclusion Among the top 10 hub genes confirmed in thymoma, CDK1, E2F2, MCM2, MKI67, JUN, and TOP2A show prognostic significance and might also play vital roles in immune surveillance and tumor progression. E2F2 might be the potential biomarker for type B2 thymoma.
- Open Access
- 7 January 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 746304
Clinical and Genetic Characteristics of Thymoma Patients With Autoimmune Hepatitis and Myocarditis
Background: Our study investigated a special series of thymoma with autoimmune hepatitis and myocarditis and tried to reveal the gene expression profiles of this series of thymoma.Methods: From 2011 to 2019, a total of 13 special thymoma patients presented with autoimmune hepatitis and myocarditis, accounting for about 1.26% of thymoma patients undergoing surgery in Beijing TongRen Hospital. Clinical data were retrospectively collected. All samples were harvested during surgical procedures, and analyzed to identify changes in gene expression using the CapitalBio mRNA microarray analysis, the Whole exome sequencing analysis (WES), qPCR and immunohistochemistry (IHC) tools.Results: After surgery, patient symptoms were relieved gradually. Levels of lactate dehydrogenase (LDH), creatine kinase MB (CK-MB), aspartate transaminase (AST), and alanine amiotransferase (ALT) increased to some extent within 1 to 3 months after surgery, and fluctuated, and then, gradually decreased close to normal within 6 months after surgery. Enrichment analysis of Kyoto Genome and Genome Encyclopedia (KEGG) pathway was performed and enrichment results were visualized. It indicated that gene expression of 5 signaling pathways, including cell cycle and p53 signaling pathway, were generally abnormal. P53 expression was up-regulated in all tumor tissues. However, IHC and qPCR analysis showed that there was no significant difference in p21 expression between normal and tumor tissue. Results of WES showed that only one driver gene-MDM4 amplified 4 fold in 53.2% thymoma cells. Further qPCR and IHC analysis confirmed the up-regulation of the expression of p53 and mdm4 in 13 thymoma patients with autoimmune hepatitis and myocarditis.Conclusion: Our study reveals the clinical and genetic characteristics of thymoma patients with autoimmune hepatitis and myocarditis. For this special category of thymoma, the up-regulation of p53 and mdm4 plays an important role in the occurrence of thymoma and autoimmune hepatitis/myocarditis.
- 7 January 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 746304
Open AccessClinical and Genetic Characteristics of Thymoma Patients With Autoimmune Hepatitis and Myocarditis
Background: Our study investigated a special series of thymoma with autoimmune hepatitis and myocarditis and tried to reveal the gene expression profiles of this series of thymoma.Methods: From 2011 to 2019, a total of 13 special thymoma patients presented with autoimmune hepatitis and myocarditis, accounting for about 1.26% of thymoma patients undergoing surgery in Beijing TongRen Hospital. Clinical data were retrospectively collected. All samples were harvested during surgical procedures, and analyzed to identify changes in gene expression using the CapitalBio mRNA microarray analysis, the Whole exome sequencing analysis (WES), qPCR and immunohistochemistry (IHC) tools.Results: After surgery, patient symptoms were relieved gradually. Levels of lactate dehydrogenase (LDH), creatine kinase MB (CK-MB), aspartate transaminase (AST), and alanine amiotransferase (ALT) increased to some extent within 1 to 3 months after surgery, and fluctuated, and then, gradually decreased close to normal within 6 months after surgery. Enrichment analysis of Kyoto Genome and Genome Encyclopedia (KEGG) pathway was performed and enrichment results were visualized. It indicated that gene expression of 5 signaling pathways, including cell cycle and p53 signaling pathway, were generally abnormal. P53 expression was up-regulated in all tumor tissues. However, IHC and qPCR analysis showed that there was no significant difference in p21 expression between normal and tumor tissue. Results of WES showed that only one driver gene-MDM4 amplified 4 fold in 53.2% thymoma cells. Further qPCR and IHC analysis confirmed the up-regulation of the expression of p53 and mdm4 in 13 thymoma patients with autoimmune hepatitis and myocarditis.Conclusion: Our study reveals the clinical and genetic characteristics of thymoma patients with autoimmune hepatitis and myocarditis. For this special category of thymoma, the up-regulation of p53 and mdm4 plays an important role in the occurrence of thymoma and autoimmune hepatitis/myocarditis.